516 related articles for article (PubMed ID: 30444646)
1. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Olgar Y; Turan B
Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
[TBL] [Abstract][Full Text] [Related]
2. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
3. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria-Targeting Antioxidant Provides Cardioprotection through Regulation of Cytosolic and Mitochondrial Zn
Olgar Y; Tuncay E; Turan B
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382470
[TBL] [Abstract][Full Text] [Related]
5. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome.
Ng HY; Kuo WH; Tain YL; Leung FF; Lee WC; Lee CT
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836340
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
Bugga P; Mohammed SA; Alam MJ; Katare P; Meghwani H; Maulik SK; Arava S; Banerjee SK
Life Sci; 2022 Oct; 307():120862. PubMed ID: 35934058
[TBL] [Abstract][Full Text] [Related]
11. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability.
Díaz-Rodríguez E; Agra RM; Fernández ÁL; Adrio B; García-Caballero T; González-Juanatey JR; Eiras S
Cardiovasc Res; 2018 Feb; 114(2):336-346. PubMed ID: 29016744
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
[TBL] [Abstract][Full Text] [Related]
14. Titin and CK2α are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats.
Durak A; Bitirim CV; Turan B
Cardiovasc Drugs Ther; 2020 Aug; 34(4):487-501. PubMed ID: 32377826
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Koyani CN; Plastira I; Sourij H; Hallström S; Schmidt A; Rainer PP; Bugger H; Frank S; Malle E; von Lewinski D
Pharmacol Res; 2020 Aug; 158():104870. PubMed ID: 32434052
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming.
Wu S; Luo X; Chen Y; Wang Z; Liu X; Sun N; Zhao J; Luo W; Zhang J; Tong X; Huang L; Liu C; Qin Z
Redox Biol; 2024 Jul; 73():103183. PubMed ID: 38759418
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
[TBL] [Abstract][Full Text] [Related]
19. Increased free Zn
Olgar Y; Durak A; Tuncay E; Bitirim CV; Ozcinar E; Inan MB; Tokcaer-Keskin Z; Akcali KC; Akar AR; Turan B
J Cell Mol Med; 2018 Mar; 22(3):1944-1956. PubMed ID: 29333637
[TBL] [Abstract][Full Text] [Related]
20. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats.
Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
